CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang
Cancer Research and Treatment. 2014;46(3):234-242.   Published online 2014 July 15    DOI: https://doi.org/10.4143/crt.2014.46.3.234

Excel Download

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
Cancer Research and Treatment. 2014;46(3):234-242   Crossref logo
Link1 Link2

359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors
European Journal of Cancer Supplements. 2004;2(8):108   Crossref logo
Link1 Link2

A phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results
European Journal of Cancer. 2002;38:S49   Crossref logo
Link1 Link2

Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies
European Journal of Cancer. 2002;38:S49   Crossref logo
Link1 Link2

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies
European Journal of Cancer. 2002;38:S54   Crossref logo
Link1 Link2

1472 POSTER A phase I study with fosfluridine tidoxil, a novel oral fluoropyrimidine, in patients with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):426   Crossref logo
Link1 Link2

First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours
European Journal of Cancer. 2002;38:S17   Crossref logo
Link1 Link2

1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours
European Journal of Cancer. 2011;47:S144-S145   Crossref logo
Link1 Link2

1454 POSTER A phase I dose-finding study of pemetrexed combined with paclitaxel in patients with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):421   Crossref logo
Link1 Link2

1448 ORAL Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors
European Journal of Cancer Supplements. 2005;3(2):419   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.